Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 15/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181877 | 0.84 | RAB9A (0.59) | HTR3ACNR1CNR2TNKS | |
| SCHEMBL23940224 | 0.76 | ALDH1A1 (0.50) | SMN1; SMN2 | |
| SCHEMBL23940153 | 0.73 | ALDH1A1 (0.50) | SMN1; SMN2CNR1CNR2 | |
| SCHEMBL23940249 | 0.73 | BRD4 (0.55) | CNR1CNR2CREBBP | |
| SCHEMBL23940236 | 0.73 | CREBBP (0.51) | SMN1; SMN2CREBBP | |
| SCHEMBL23940243 | 0.72 | ALDH1A1 (0.59) | SMN1; SMN2CREBBP | |
| SCHEMBL3924368 | 0.72 | ALDH1A1 (0.53) | — | |
| SCHEMBL15458754 | 0.72 | SMN1; SMN2 (0.51) | SMN1; SMN2CREBBP | |
| SCHEMBL3832654 | 0.71 | P2RX3 (0.41) | HTR3ACNR1CNR2 | |
| SCHEMBL23940202 | 0.71 | LMNA (0.46) | SMN1; SMN2CNR1CNR2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | TYK2, JAK3, JAK1 | HTR3A 2012/4885SMN1; SMN2 2940/4885CNR1 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.